Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD

$167.47

Updated: 04/11/2026, 05:56:41

Market Cap
$207.66B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US

No historical data available

Company Profile

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

USD
NASDAQ
CEO: Daniel O'Day
Employees: 17,000
https://www.gilead.com
Asset Summaries
Latest generated summaries for GILD

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
GILD-10-k-fy2025.html3.0 MBtext/htmlENFiled 24/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 61 KPI observations

Revenue

$29.4B

FY 2025 · Reported

Net income

$8.5B

FY 2025 · Reported

Gross margin

78.8%

FY 2025 · Calculated

Free cash flow

$9.5B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$1.9B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Reported sales by product or service for FY 2025. Shares and growth are calculated from the filing values.
Product / serviceSalesShare of salesYoY growthBy reported area
Total revenues
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$29,443mN/A+2.4%Not disclosed by product and area
Total product sales
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$28,915mN/A+1.1%Not disclosed by product and area
HIV
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$20,752mN/A+5.8%Not disclosed by product and area
Total Oncology
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$3,236mN/A-1.6%Not disclosed by product and area
Liver Disease
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$3,217mN/A+6.5%Not disclosed by product and area
Cell Therapy
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$1,839mN/A-6.8%Not disclosed by product and area
Trodelvy
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$1,397mN/A+6.2%Not disclosed by product and area
Veklury
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$911mN/A-49.4%Not disclosed by product and area
Other
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$799mN/A-10.1%Not disclosed by product and area
Royalty/contract/other
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”
$527mN/A+266.0%Not disclosed by product and area

Other offerings mentioned without separate sales

Biktarvy franchise and patent litigation settlements
Yeztugo (lenacapavir) PrEP launches

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureUnited States: 70.9% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)Europe: 17.2% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

Revenue exposure by reported geography
FY 2025 share of total net sales. Regional segments are kept as regions rather than falsely allocated to individual countries.
United States
+70.9%
Europe
+17.2%
Other markets
+11.9%

How the business makes money

Company overview

Biopharma focused on HIV, viral hepatitis, COVID-19, cancer; 35+ countries; HQ Foster City, CA

99%
Source evidence
“We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.”

Company overview

Biopharma company: HIV, viral hepatitis, COVID-19, cancer; >35 countries; HQ Foster City, CA

98%
Source evidence
“We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.”

Royalty, contract and other revenues

Royalties on outbound IP licenses and collaboration payments

92%
Source evidence
“We also generate revenues from other activities, including royalties for outbound licenses of our intellectual property, sales of certain intellectual property and other payments received from our collaborations with third-party partners.”

US non-retail government customers drive purchase volatility

Non-retail sector (ADAPs, VA, correctional facilities, large HMOs) has inconsistent buying patterns causing quarter-over-quarter fluctuations

93%
Source evidence
“the non-retail sector in the U.S., which includes government institutions, including state AIDS Drug Assistance Programs, the U.S. Department of Veterans Affairs, correctional facilities and large health maintenance organizations, tends to be less consistent in terms of buying patterns”

Distribution model

US exclusively wholesale; international via own teams, distributors or partners; marketing subsidiaries in >35 countries

95%
Source evidence
“We sell and distribute most of our products in the U.S. exclusively through the wholesale channel.”

Exclusive US wholesaler/distributor channel

Most US products sold exclusively through wholesaler/distributor channel with inventory-driven quarter-to-quarter fluctuations

95%
Source evidence
“We sell and distribute most of our products in the U.S. exclusively through the wholesaler/distributor channel.”

Biktarvy franchise and patent litigation settlements

Biktarvy $14,334M sales; generic entry pushed to April 1, 2036 (vs prior Dec 2033)

98%
Source evidence
“the earliest date the three generic manufacturers can market a generic version of full dose Biktarvy in the U.S. is April 1, 2036, subject to standard acceleration provisions. This is more than two years later than our previous loss of exclusivity projection for Biktarvy (December 2033).”

HIV product portfolio

HIV franchise: Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo

98%
Source evidence
“In 2025, our commercial portfolio included more than 25 therapies, including the following products and collaboration products with approved indications in the U.S.: HIV”

Yeztugo (lenacapavir) PrEP launches

Yeztugo approved in US and EC-authorized as twice-yearly PrEP; PEPFAR partnership for up to 2M people over 3 years

97%
Source evidence
“Announced a partnership with the U.S. State Department and the U.S. President’s Emergency Plan for AIDS Relief (“PEPFAR”) to deliver lenacapavir for HIV PrEP for up to two million people over three years”

Oncology and other products

Oncology: Tecartus, Trodelvy, Yescarta; Other: AmBisome, Veklury

97%
Source evidence
“Yescarta® (axicabtagene ciloleucel), a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients”

Liver disease products

Liver Disease: Epclusa, Livdelzi, Vemlidy

97%
Source evidence
“Epclusa® is an oral formulation of a once-daily single-tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus ("HCV") infection”

Revenue by geography 2025

2025: US $20,876M, Europe $5,064M, Rest of World $3,503M

99%
Source evidence
“Total revenues$20,876 $5,064 $3,503 $29,443 $20,591 $4,634 $3,529 $28,754 2 %”

Product sales by franchise 2025 vs 2024

Total revenues $29,443M (2025) vs $28,754M (2024), +2%; HIV $20,752M (+6%), Liver Disease $3,217M (+6%), Veklury $911M (-49%), Oncology $3,236M (-2%)

99%
Source evidence
“Total HIV16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 6 %”

Operations and dependencies

US CAR T manufacturing facilities

In-house CAR T-cell therapy manufacturing facilities in California, Maryland and the Netherlands

95%
Source evidence
“our in-house CAR T-cell therapy manufacturing facilities in California, Maryland and the Netherlands, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing”

Own manufacturing facilities and licenses

Manufacturing facilities in California, Canada, Ireland and Netherlands

92%
Source evidence
“Our manufacturing facilities located in California also must be licensed by the State of California in compliance with local regulatory requirements. Our manufacturing facilities in Canada, Ireland and Netherlands also must obtain local licenses and permits”

Outsourced clinical trials to CROs

Relies on third-party CROs for most clinical studies

95%
Source evidence
“We rely on third-party contract research organizations to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalysis.”

Positioning and strategy

Interius BioTherapeutics acquisition

Acquired Interius BioTherapeutics for ~$350 million (in vivo CAR therapeutics)

97%
Source evidence
“Announced the acquisition of Interius BioTherapeutics, Inc. (“Interius”), a privately held biotechnology company developing in vivo chimeric antigen receptor therapeutics, for approximately $350 million.”

Arcellx acquisition agreement

Definitive agreement to acquire Arcellx (anitocabtagene autoleucel CAR-T); expected close Q2 2026

97%
Source evidence
“Announced that we entered into a definitive agreement to acquire all of the outstanding common stock of Arcellx, Inc. ... This transaction is anticipated to close during the second quarter of 2026”

$32 billion U.S. investment through 2030

$32B planned U.S. investment through 2030; Foster City Technical Development Center groundbreaking

95%
Source evidence
“Announced ground-breaking on a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City, California as part of a planned $32 billion investment in the U.S. through 2030.”

R&D portfolio breadth

50+ clinical-stage programs; 2026 FDA decisions on two 1L breast cancer therapies and an HIV treatment option

96%
Source evidence
“Our R&D portfolio includes over 50 clinical-stage programs across our core therapeutic areas. We expect updates in 2026 ... including FDA decisions related to two first-line breast cancer therapies and an additional HIV treatment option.”

Phase 3 / regulatory-review pipeline in virology

Virology Phase 3: bulevirtide (HDV), once-yearly lenacapavir PrEP, bictegravir/lenacapavir, islatravir/lenacapavir (with Merck)

96%
Source evidence
“LenacapavirA once-yearly injection of lenacapavir, an HIV-1 capsid inhibitor, is being evaluated for HIV PrEP.”

Phase 3 / regulatory-review pipeline in oncology

Oncology: anitocabtagene autoleucel (Arcellx), sacituzumab govitecan TNBC filings, +pembrolizumab with Merck

95%
Source evidence
“In collaboration with Arcellx, Inc. ("Arcellx")(1), a Biologics License Application has been filed with FDA for anitocabtagene autoleucel, a CAR T-cell therapy”

Strategic priorities refreshed late 2025

Long-acting HIV, oncology/inflammation pipeline, AI adoption, investment prioritization, collaboration; 10+ transformative therapies by 2030

98%
Source evidence
“Our strategic priorities, as refreshed in late 2025, to deliver on these ambitions include: (i) maximize impact of long-acting HIV therapies; (ii) accelerate our pipeline build in oncology and inflammation; (iii) adopt and scale artificial intelligence to transform how we work; (iv) prioritize investments for highest impact; and (v) strengthen collaboration to accelerate innovation.”

$32 billion US investment through 2030

$32 billion multi-year investment in the U.S. through 2030 for manufacturing expansion and accelerated R&D

97%
Source evidence
“including our initiative to invest $32 billion in the U.S. through 2030”

Risks, financing, and outlook

2026 outlook

2026: overall product sales growth on HIV demand; offsets from US policy impacts, declining Veklury and Cell Therapy

97%
Source evidence
“we expect to see continued growth for our product sales overall, bolstered by increased demand in our HIV business ... an expected decrease in our Veklury product sales due to lower rates of COVID-19-related hospitalizations and an expected decrease in our Cell Therapy product sales reflecting ongoing competitive headwinds.”

U.S. government pricing agreement

Agreement with U.S. government to lower cost of medicines for Americans

90%
Source evidence
“Announced an agreement with the U.S. government to lower the cost of medicines for Americans, reinforcing a commitment to U.S.-based innovation, affordability and global health leadership.”

US drug pricing and reimbursement regulation

Medicare/Medicaid rebates, 340B discounts; IRA and One Big Beautiful Bill Act impacts expected

94%
Source evidence
“A significant portion of our sales of the majority of our products are subject to substantial discounts from their list prices, including rebates to Medicare and Medicaid agencies or discounts to covered entities under Section 340B of the Public Health Service Act”

Manufacturing and healthcare fraud/abuse regulation

cGMP, FDA REMS for CAR T, anti-kickback/false claims scrutiny

93%
Source evidence
“For our cell therapy products, we are required by FDA to comply with the Risk Evaluation and Mitigation Strategy program”

Proposed BIOSECURE Act and ABC Safe Drug Act exposure

BIOSECURE Act and ABC Safe Drug Act could raise costs or restrict supply of materials used in clinical trials and manufacturing

92%
Source evidence
“the ABC Safe Drug Act (which, among other things, could prohibit U.S. federal health care programs from purchasing drugs and drug ingredients manufactured in China), has the potential to adversely impact our ability to receive goods or services from such entities”

HIV revenue concentration

Substantial revenue concentration in HIV products; may lose share to competitive products including generics

98%
Source evidence
“We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection.”

Cell therapy manufacturing and supply risk

Yescarta/Tecartus CAR T-cell risks: in-house manufacturing (CA, MD, Netherlands), apheresis/logistics dependencies, REMS until June 2025, 2024 boxed warning on secondary T-cell malignancies

97%
Source evidence
“in January 2024, FDA instituted a class labeling change for all approved CAR T-cell therapies, including a "boxed warning" about the possible risk of secondary T-cell malignancies in patients treated with CAR T-cell therapy.”

Pipeline setbacks in oncology and HIV

STAR-221 discontinued; ASCENT-07 missed PFS endpoint; FDA clinical hold on GS-1720/GS-4182 HIV trials

96%
Source evidence
“Announced that FDA had placed a clinical hold on the HIV treatment trials of GS-1720 and/or GS-4182, including the WONDERS-1 and WONDERS-2 trials.”

Pricing and reimbursement pressure

Products subject to pricing/reimbursement pressure from government agencies and third-party payers including required discounts and rebates

95%
Source evidence
“As our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices.”

Veklury COVID-19 demand uncertainty

Veklury sales tied to COVID-19 infection rates, hospitalizations, and vaccine/alternative treatment availability

95%
Source evidence
“Veklury sales generally reflect COVID-19 related rates and severity of infections and hospitalizations, as well as the availability, uptake and effectiveness of vaccines and alternative treatments for COVID-19, and future sales in the short- and long-term remain uncertain.”

FDA regulatory compliance and agency disruption

Complex FDA/EMA regulatory compliance risk including potential REMS, penalties, recalls and agency disruption from budget cuts/layoffs

93%
Source evidence
“changes or disruptions at FDA or other regulatory agencies, including as a result of budget cuts and employee layoffs, could impair the ability of these agencies to timely review and process our applications”

European cost containment inventory drawdown

European budget crises and cost containment have reduced distributor inventories of Gilead products

90%
Source evidence
“In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe.”

Material exposure graph

HIV treatment and prevention products
Revenue Exposure

Substantial portion of revenue comes from HIV products, exposing revenue to generics and competitive share shifts.

Relevance 98·Dependency 95·Confidence 98
Source evidence
“We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection.”
Biktarvy
Demand Driver

Biktarvy is the largest product at $14,334M of $29,443M total revenues, up 7% in 2025.

Relevance 95·Dependency 75·Confidence 97
Source evidence
“Biktarvy$11,467 $1,676 $1,190 $14,334 $10,855 $1,509 $1,060 $13,423 7 %”
Yeztugo (lenacapavir)
Demand Driver

HIV business growth is expected to be bolstered by demand including newly launched twice-yearly PrEP lenacapavir in the U.S. and Europe.

Relevance 95·Dependency 70·Confidence 95
Source evidence
“we delivered growth in our HIV product sales, introduced Yeztugo, the first and only twice-yearly HIV pre-exposure prophylaxis (“PrEP”) option available in the U.S.”
Cardinal Health, Cencora, McKesson
Customer Exposure

~90% of US gross product sales historically flow through three wholesalers, making revenue dependent on their inventory behavior.

Relevance 92·Dependency 90·Confidence 98
Source evidence
“approximately 90% of our gross product sales in the U.S. have been to three wholesalers—Cardinal Health, Inc., Cencora, Inc. and McKesson Corporation”
HIV franchise
Demand Driver

HIV products including Biktarvy, Descovy and new PrEP agent Yeztugo anchor the commercial portfolio and pipeline.

Relevance 90·Dependency 80·Confidence 95
Source evidence
“Yeztugo® is an HIV-1 capsid inhibitor in tablet form for oral use and as an injection for subcutaneous use. Yeztugo is indicated for PrEP to reduce the risk of sexually acquired HIV-1”
United States
Revenue Exposure

U.S. generated $20,876M of $29,443M total 2025 revenues (~71%), and U.S. policy developments are a stated headwind.

Relevance 90·Dependency 75·Confidence 98
Source evidence
“Total revenues$20,876 $5,064 $3,503 $29,443”
Three large US wholesalers (Cardinal Health, Cencora, McKesson)
Customer Exposure

Approximately 90% of US gross product sales flow through three wholesalers, creating significant channel concentration.

Relevance 85·Dependency 85·Confidence 97
Source evidence
“Historically, approximately 90% of our gross product sales in the U.S. have been to three large wholesalers—Cardinal Health, Inc., Cencora, Inc. and McKesson Corporation—and their specialty distributor affiliates.”
Medicare/Medicaid rebates and 340B discounts; IRA and OBBBA
Revenue Exposure

Government pricing regulation and mandated discounts limit net prices of the majority of products; IRA and OBBBA impacts explicitly flagged.

Relevance 85·Dependency 70·Confidence 93
Source evidence
“including rebates to Medicare and Medicaid agencies or discounts to covered entities under Section 340B of the Public Health Service Act ("340B")”
U.S. drug pricing policy
Regulatory Exposure

U.S. policy-related developments expected to partially offset 2026 growth; company entered an agreement with the U.S. government on medicine pricing.

Relevance 85·Dependency 60·Confidence 90
Source evidence
“the impact of various policy-related developments in the U.S.”
Lupin, Cipla, Laurus Labs
Legal Exposure

Biktarvy patent litigation settlements with generic manufacturers establish April 1, 2036 earliest generic entry, reducing near-term LOE risk.

Relevance 85·Dependency 55·Confidence 95
Source evidence
“settlement agreements to resolve Biktarvy patent litigation with generic manufacturers Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd.”
California, Maryland, Netherlands
Manufacturing Dependency

CAR T-cell therapies depend on in-house facilities in California, Maryland and the Netherlands; delays or quality issues would affect delivery.

Relevance 80·Dependency 75·Confidence 95
Source evidence
“our in-house CAR T-cell therapy manufacturing facilities in California, Maryland and the Netherlands”
Veklury
Competitive Exposure

Veklury sales fell 49% in 2025 and are expected to decline further with lower COVID-19 hospitalization rates.

Relevance 80·Dependency 40·Confidence 96
Source evidence
“an expected decrease in our Veklury product sales due to lower rates of COVID-19-related hospitalizations”
Cell Therapy (Yescarta/Tecartus)
Competitive Exposure

Cell Therapy sales declined 7% in 2025 with expected further 2026 decline due to ongoing competitive headwinds.

Relevance 75·Dependency 45·Confidence 95
Source evidence
“an expected decrease in our Cell Therapy product sales reflecting ongoing competitive headwinds.”
BIOSECURE Act / ABC Safe Drug Act
Regulatory Exposure

Proposed US legislation could restrict goods/services from certain foreign-owned entities used in clinical trials and manufacturing.

Relevance 70·Dependency 60·Confidence 92
Source evidence
“has the potential to adversely impact our ability to receive goods or services from such entities, including certain of which we use in connection with our clinical trials and our clinical and commercial manufacturing”
PEPFAR / Global Fund
Demand Driver

Partnership with U.S. State Department PEPFAR and Global Fund to deliver lenacapavir PrEP for up to two million people over three years supports HIV revenue in supported countries.

Relevance 70·Dependency 35·Confidence 90
Source evidence
“deliver lenacapavir for HIV PrEP for up to two million people over three years in countries supported by both PEPFAR and the Global Fund.”
Third-party contract research organizations
Supplier Dependency

Most clinical studies are performed by third-party CROs, making pipeline execution dependent on them.

Relevance 65·Dependency 70·Confidence 94
Source evidence
“We rely on third-party contract research organizations to perform most of our clinical studies”
Veklury
Revenue Exposure

Veklury sales depend on COVID-19 infection rates and vaccine/treatment availability, making demand episodic and uncertain.

Relevance 65·Dependency 50·Confidence 95
Source evidence
“Veklury sales generally reflect COVID-19 related rates and severity of infections and hospitalizations”
US government institutions (ADAPs, VA, HMOs)
Demand Driver

US non-retail government/institutional buying driven by federal/state budget cycles causes revenue fluctuations not tied to patient demand.

Relevance 60·Dependency 55·Confidence 93
Source evidence
“Federal and state budget pressures, as well as the annual grant cycles for federal and state funds, may cause purchasing patterns to not reflect patient demand for our products.”
Merck & Co., Inc.
Technology Dependency

Merck collaboration on islatravir + lenacapavir long-acting HIV treatment and sacituzumab govitecan + pembrolizumab oncology combination.

Relevance 55·Dependency 45·Confidence 93
Source evidence
“In collaboration with Merck & Co., Inc. ("Merck")(1), an oral combination of Merck's islatravir and lenacapavir is being evaluated as a long-acting HIV treatment”
Europe (EU markets)
Revenue Exposure

European budget crises and cost containment cause channel inventory reductions and purchasing pattern variations.

Relevance 55·Dependency 45·Confidence 90
Source evidence
“we believe these measures have caused some government agencies and other purchasers to reduce inventory of our products in the distribution channels”
Janssen (Johnson & Johnson Innovative Medicine)
Revenue Exposure

Odefsey uses Janssen's rilpivirine and Symtuza is commercialized by Janssen, with Gilead receiving a revenue share.

Relevance 55·Dependency 40·Confidence 93
Source evidence
“Symtuza is commercialized by Janssen, and we receive a share in revenue for the components that we contribute.”
Full company information
Latest profile, trading, valuation, and identifier data stored for GILD.
Share price
$167.47
Market cap
$207.66B
Exchange
NASDAQ
Currency
USD
CEO
Daniel O'Day
Employees
17,000
IPO date
22/01/1992
Beta
0.332
Last dividend
$0.00
Day range
$167.43 – $171.99
52-week range
$116.88 – $175.65
1-day performance
-1.68%
1-year performance
43.28%
Current drawdown (1Y)
-4.66%
CIK
0000882095
CUSIP
375558103
ISIN
US3755581036
Created
07/12/2025, 04:13:56
Last update
04/11/2026, 05:56:41

Track Gilead Sciences, Inc. with an AI analyst

See which prediction-market events move GILD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to GILD from your Railway `news_articles` table.

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

Zacks Investment Research • STOCK • 11/06/2026, 16:26:14

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 22:12:11

Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study

Zacks Investment Research • STOCK • 09/06/2026, 18:36:09

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Business Wire • STOCK • 08/06/2026, 18:35:00

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Business Wire • STOCK • 05/06/2026, 05:00:00

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

GlobeNewsWire • STOCK • 04/06/2026, 18:15:00

GILD Reports Positive Results From Late-Stage Liver Disease Study

Zacks Investment Research • STOCK • 03/06/2026, 14:21:07

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research • STOCK • 03/06/2026, 12:00:35

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

Benzinga • STOCK • 02/06/2026, 15:47:38

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)

Business Wire • STOCK • 27/05/2026, 04:00:00

GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy

Zacks Investment Research • STOCK • 25/05/2026, 14:01:19

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

MarketBeat • STOCK • 24/05/2026, 11:04:21